
About this episode
The US Food and Drug Administration is supposed to make sure the medications we take are effective–and safe. But when a small independent lab in Connecticut called Valisure started testing popular drugs and health products, it turned up some alarming results–including carcinogens and other dangerous substances. You might think the FDA would welcome this information. Not so fast.
Bloomberg reporter Anna Edney joins this episode to talk about how Valisure’s findings have shined a light on serious flaws in the way medications are tested and approved. Valisure CEO David Light talks with Wes about how his lab identifies harmful substances in products, and how the FDA responded when he came forward with his lab’s findings. Then Dr. Diana Zuckerman, President of the National Center for Health Research, stops by to answer the question: Is the FDA too close to the companies it oversees?
Learn more about this story here: https://bloom.bg/3EdVico
Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time Big Take publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Big Take

So Could AI 'Kill Us All'?
Big Take

Trump Needs a Win. Enter His Venezuela Oil Deal
Big Take

Why the Bond Market Has Everyone On Edge
Big Take

Americans Are Spending Billions to Help Their Pets Live Longer
Big Take